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1. INTRODUCTION 
Sexually transmitted infections are a major problem for medicine and for public health services 
worldwide. More than 30 sexually transmittable pathogenic micro-organisms are known, including 
bacteria, viruses, fungi, protozoa and ectoparasites [1]. According to estimates from the World 
Health Organisation more than 333 million of bacterial sexually transmitted infections occur 
worldwide per year [2]. Sexually transmitted infections, by their nature, affect individuals, within 
partnerships and larger sexual networks, and in turn populations. 
This report focuses on three bacterial sexually transmitted infections in Switzerland that are 
Chlamydia trachomatis, Neisseria gonorrhea and Treponema pallidum (syphilis) in Switzerland. The 
prevalence of these infections has been increasing alarmingly for a decade. All three infections can be 
asymptomatic and their diagnosis and treatment can therefore occur too late or worse not at all, even 
though treatments are available. This is an important problem as untreated sexually transmitted 
infections may cause complications such as ascending infections, infertility, ectopic pregnancies and 
serious long-term neurological sequels. The consequences of these infections should not be 
underestimated. They constitute a significant public health burden as well as serious financial burden. 
The increases in chlamydia, syphilis and gonorrhea infections have also been observed in many 
European countries.  Countries, where rising numbers of sexually transmitted infections have been 
observed, have reacted in different ways. Some have developed clinical guidelines or implemented 
screening programs, while others are still in their observational phase.  
The aim of this mémoire is to assess whether Switzerland is doing enough regarding the 
prevention of chlamydial, syphilis and gonorrheal infections. After first describing the infections,   
surveillance systems of sexually transmitted infections are assessed, then the epidemiological trends 
of these three infections are described, and finally the prevention measures implemented in 
Switzerland to respond to the increasing number of infections are described. The reaction of the 
United Kingdom to the same problem is reported for comparison. 
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2. DESCRIPTION OF SYPHILIS, GONORRHEA AND 
CHLAMYDIA INFECTIONS 
2.1 TREPONEMA PALLIDUM (SYPHILIS) 
2.1.1 Transmission 
Syphilis is a contagious disease essentially transmitted by sexual contacts. It is a bacterial infection. 
The causal agent is Treponema pallidum. It is a benign disease if treated early but can be serious if it is 
unknown or neglected. It is contagious during the first two to four years [3]. It is an obligate human 
parasite, and there are no reservoirs for this organism in animals or in the environment [4]. Most 
cases of syphilis are acquired through direct sexual contact. A person can get syphilis during vaginal, 
oral and anal sex.  Transmission by sexual contact requires exposure to moist mucosal or cutaneous 
lesions, and therefore a person is able to transmit syphilis only during the first few years of infection. 
Syphilis is also transmitted vertically from an infected mother to the fetus by transplacental passage 
of treponemes, causing congenital syphilis. Infection in pregnant women may also cause stillbirth, 
and prematurity. Rates of acquisition of syphilis from an infected sexual partner have been estimated 
at about 30% [5]. Transmission to the fetus in utero has been documented as early as the ninth week 
of pregnancy. Women remain potentially infectious for the fetus for many years, although the risk of 
infecting the fetus declines gradually during the course of untreated illness; after about 8 years there 
is little risk even in the untreated mother [5]. 
 
2.1.2 Clinical manifestation 
Syphilis has an evolution that can be described in 4 stages [3]. 
 
• Primary syphilis 
The chancre (genital sore) is the first manifestation of syphilis infection and develops at the site of 
inoculation. The chancre develops from 10 to 90 days (average 3 weeks) from exposure. The 
lesion is usually single but may be multiple. It is usually painless and if untreated it heals in a few 
weeks [5]. 
 
• Secondary syphilis 
Secondary syphilis occurs up to 6 months after the healing of the primary lesion. It is a systemic 
disease characterized by low-grade fever, malaise, sore throat, headache, adenopathy, and 
cutaneous or mucosal rash. This second stage of illness may be accompanied by alopecia, and up 
to 10% of patients have mild hepatitis. The secondary stage rash will spontaneously disappear in 4 
to 12 weeks and it may reoccur in approximately 25% of untreated patients [6]. The systemic 
nature of secondary syphilis and its multiple organ involvement is frequently overlooked leading 
to misdiagnosis [5]. 
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• Latency 
By definition, persons with historical or serological evidence for syphilis but with no clinical 
manifestations have latent syphilis. Latency has been somewhat arbitrarily divided into early 
latency and late latency, on the basis of the time when untreated individuals are likely to have 
spontaneous infectious relapses. Latency can last for many years; approximately two-third of 
untreated patient with latent syphilis will remain in this stage for the remainder of their lives. 
Spontaneous cures are thought to be unusual [4]. 
 
• Tertiary syphilis 
Tertiary syphilis affects about 35% of untreated patients and usually occurs 20-40 years after the 
onset of infection. The disease may occur in the following forms either singly or in combination: 
mucocutaneous, osseous, neural and visceral, particularly the heart and great vessels. The principal 
morbidity and mortality of syphilis in adults is due to these later manifestations. Late 
complications are relatively less of a problem than in the preantibiotic era, but alertness to the 
possibility of late syphilis and awareness of the multiple clinical manifestations of late syphilis are 
crucial if these forms of disease are to be diagnosed and treated properly [5] [6]. 
 
2.1.3 Diagnosis and treatment of T. pallidum 
The diagnosis of syphilis in most patients is made by serological testing. The two types of tests used 
are biologically nonspecific tests and specific treponemal tests [7]. In Switzerland, the test used for 
screening is a nonspecific test called “the venereal diseases research laboratory”. This test gives 
information on the disease’s activity. If positive, the diagnosis is confirmed by a specific treponemal 
test, usually the T. pallidum particle agglutination or the fluorescence treponema antibodies. Most 
patients who have treponemal tests will have reactive tests for the remainder of their lives, regardless 
of the treatment or disease activity [4]. Both tests are very sensitive, around 80% for the first stage of 
the infection, and 100% for the second and third stage. 
Intramuscularly administered penicillin is the preferred treatment for syphilis, although other 
antibiotics, including tetracyclines, macrolides and cephalosporins, have also been used. These 
alternatives have been useful in treating penicillin-allergic patients. During the past decades, and 
especially since 2004, reports of treatment failures and antibiotic resistance associated with 
macrolides have been reported. This indicates a need for further antibiotic drug development and 
surveillance for resistance in T. pallidum [8]. 
 
2.2 NEISSERIA GONORRHEA 
Gonorrhea is a bacterial infection that primarily affects male and female genital mucosa but can 
involve other areas of the body. Gonorrhea is a disease found only in humans; it has no other known 
reservoir [7].  
 
2.2.1 Transmission 
Transmission of N. gonorrhea is primarily by sexual contact. The efficiency of gonorrhea transmission 
depends on anatomic sites infected and exposed as well as the number of exposures. The risk of 
acquiring urethral infection for a man following a single episode of vaginal intercourse with an 
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infected woman is estimated to be 20%, rising to an estimated 60 to 80% following four exposures. 
The risk of infection for women after a single exposure to an infected man is 50%. It is likely that the 
single-exposure transmission rate from male to female is higher that from female to male, in part 
because of retention of the infected ejaculate within the vagina. The risk of transmission by other 
types of sexual contact is less well defined. Gonorrhea transmission through rectal intercourse is 
relatively efficient and pharyngeal gonorrhea is readily acquired by fellatio [5],[6],[7]. 
 
2.2.2 Clinical manifestation 
Uncomplicated gonococcal infections: 
Gonorrhea is manifested by a broad spectrum of clinical presentation, including asymptomatic and 
symptomatic local infections, local complicated infections and systemic disseminations [5].  
• Urethral infection in men 
Acute anterior urethritis is the most common manifestation of gonococcal infection in men. The 
majority of men develop symptoms within 2 to 5 days. The predominant symptoms are urethral 
discharge or dysuria. The severity of symptoms is partly determined by the infecting strain of N. 
gonorrhea. Without treatment, the usual course of gonococcal urethritis is spontaneous resolution 
over a period of several weeks [5]. 
• Urogenital infection in women 
The incubation period for urogenital gonorrhea in women is less certain and probably more 
variable than in men, but most women who develop local symptoms apparently do so within 10 
days of infection. The most common symptoms are vaginal discharge, dysuria and intermenstrual 
uterine bleeding. The clinical assessment of women for gonorrhea is often cofounded by the 
nonspecificity of these signs and symptoms and by the high prevalence of coexisting cervical or 
vaginal infections, like for example Chlamydia trachomatis [5]. 
• Rectal infection 
The rectal mucosa is infected in 35 to 50% of women with gonococcal cervicitis and is a frequent 
site of infection in homosexual men. Most rectal infections in women occur without 
acknowledged rectal sexual contact and are assumed to result from perineal contamination with 
infected cervical secretions [5].  
• Pharyngeal infection 
Transmission of pharyngeal gonorrhea to sex partners is possible, thus pharyngeal gonococcal 
infection may be greater than previously appreciated and may now be an important source of 
urethral gonorrhea in MSM [5]. 
 
Complicated gonococcal infections 
• Local complications in men 
In men, the most common local complication of gonococcal urethritis is epididymitis. At present, 
the most common causes of acute epididymitis in patients under 25 years old are C. trachomatis 
and N. gonorrhea or both. Another complication is decreased fertility [5]. 
• Local complication in women 
Pelvic inflammatory disease (PID) is the most common complication of gonorrhea in women, 
occurring in an estimated 10 to 20% of those with acute gonococcal infections. PID is the result 
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of post-infectious inflammation of female upper genital tract that includes salpingitis, 
endometritis and inflammation of fallopian tubes. In addition to being the most common 
complication, it is as well the most important in terms of public health impact, because of both its 
acute manifestations and its long-term sequelae. PID if untreated may lead to infertility, ectopic 
pregnancy and chronic pelvic pain [9]. Reported complications of genital gonorrhea in pregnancy 
include spontaneous abortion, premature rupture of fetal membrane, premature delivery and 
other syndromes in the new born [5]. 
 
Systemic complications: disseminated gonococcal infection 
Disseminated gonococcal infection with septicemia and infection of skin and joints occurs in 1% to 
3% of infections [7]. Recognition of patients with disseminated gonococcal infection is sometimes 
delayed because of the wide variety of clinical findings associated with this syndrome [5]. 
 
2.2.3 Diagnosis and treatment of N. gonorrhea 
Nucleic acid amplification tests (NAAT) are the most sensitive tests available for the diagnosis of N. 
gonorrhea. A major advantage of NAATs is the ability to use them with noninvasively collected 
specimens. It can be used to test first catch urine and vaginal swab specimen. The ability to use first 
catch urine and vaginal swab means that specimens can be collected in places other than traditional 
clinical settings.  Noninvasive collection of specimens has made it far easier to test asymptomatic 
individuals [10].  
Over the past 60 years, N. gonorrhea has developed resistance to multiple classes of antimicrobials. 
Sulfanilamides were used for gonococcal treatment in 1936, but were short lived because of the rapid 
emergence of resistance by 1945. Penicillin became the recommended antimicrobial regimen for the 
next 40 years. In 1985, because of emerging penicillin resistance, cephalosporine and fluroquinolone 
became a recommended regimen for the treatment of uncomplicated gonococcal infections. But 
today, because of the emergence of quinolone resistant N. gonorrhea, the current recommended 
gonorrhea treatment is cephalosporin. Given the possible emergence of cephalosporin resistance, 
other effective therapeutic regimens and new agents for gonorrhea are urgently needed [11].  
 
2.3 CHLAMYDIA TRACHOMATIS 
Chlamydia trachomatis is a bacterial infection. Chlamydia has a very limited host range, with infections 
restricted to humans and one strain responsible for mouse pneumonitis. The species has been 
subdivided into 3 biovars: trachoma, lymphogranuloma venereum (LGV) and a third biovar that is 
specific to the mouse [7]. New variants of C. trachomatis are isolated from time to time [12]. 
 
2.3.1 Transmission 
Transmissibility of chlamydia infections from women to men and inversely has not been extensively 
studied. Transmissibility from female to male has been estimated at 28% and from male to female, it 
is around 45% [5]. Chlamydia can be transmitted during vaginal, anal sex and oral sex [5]. 
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2.3.2 Clinical manifestation 
• Infections in men 
C. trachomatis is responsible for a wide range of clinical manifestations. Chlamydial infections 
among men were thought to be symptomatic. However, it has recently become apparent that as 
many as 50% of chlamydial infections in men may be asymptomatic [9]. Non specific symptoms, 
such as dysuria or perimeatal tingling can develop. C. trachomatis can cause urethritis, epididymitis 
and proctotis. 
Approximately 35% to 50% of cases of nongonococcal urethritis are caused by C. trachomatis. 
Chlamydial urethral infections are more often asymptomatic than gonococcal urethral infections, 
and when symptoms occur they are milder [9]. 
 
• Infections in women 
One of the challenges of diagnosing chlamydial infection is that at least 70% of infected women 
are asymptomatic. Non specific symptoms, such as abnormal vaginal discharge, intermenstrual 
bleeding and dysuria can develop [9]. 
Chlamydial infections can cause urethritis, cervicitis and salpingitis. Untreated chlamydial 
infection may lead to PID in 20-40% of infected women. PID will eventually have for 
consequences infertility, ectopic pregnancy and chronic pelvic pain if untreated. There are no data 
on how long it takes for untreated chlamydial infection to develop PID [8]. The clinical symptoms 
of PID are non specific and can be easily missed in women with mild symptoms. Unfortunately, 
there might not be a relationship between the severity of the symptoms and the severity of the 
disease progression. The most common symptoms of PID are lower abdominal pain, abnormal 
vaginal discharge or bleeding [9]. 
 
• Other clinical manifestations 
Repeated conjunctival infection with C. trachomatis may lead to chronic inflammation of the 
conjunctiva. The subsequent scarring of conjunctiva causes the eye lid to turn in and to scar the 
cornea; it can result in blindness if untreated [7]. 
 
2.3.3 Diagnosis and treatment of C. trachomatis 
Nucleic acid amplification test (NAAT) is considered the test of choice for diagnosing C. trachomatis 
infections. NAAT can use different testing platforms. Each platform employs a single nucleic acid 
target. The use of multiple testing platforms should ensure the detection of new variant C. trachomatis 
strains [13]. NAAT can be used on first void urine specimens and even with self obtained vaginal or 
vulvar swabs. It has a high sensitivity (more than 90%) and high specificity (99%) [14]. 
Macrolide is the best choice for the treatment of chlamydial infections. A single dose of 1g of 
azithromycin is sufficient to treat uncomplicated urethral, cervical or rectal chlamydial infections [9]. 
To date, no antibiotics resistance has been observed [15]. 
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3.  SURVEILLANCE SYSTEMS FOR SEXUALLY TRANSMITTED 
INFECTIONS IN SWITZERLAND 
3.1 DESCRIPTION OF SURVEILLANCE SYSTEMS 
Public Health surveillance is the ongoing systematic collection, analysis, interpretation, and 
dissemination of health events data used in public health activities. These activities aim to reduce 
morbidity and mortality and to improve health in general. Surveillance of sexually transmitted 
infections (STI) should provide information for action to control their spread. Surveillance systems 
can collect information about cases or diseases diagnosed in all settings (comprehensive surveillance), 
or the information can be collected through a sample of healthcare providers (Sentinel Surveillance). 
Ideally a surveillance system should provide consistent information according to time, place and 
person so that interventions can be targeted appropriately [16]. 
The Swiss surveillance system was assessed in 2005, and this evaluation led to the adaptation of 
the surveillance system in 2006. That year, as a consequence, there was a modification to the 
Ordinance on medical doctors’ and laboratories’ notifications [17]. Before 2006, the Swiss Federal 
Office of Public Health (SFOPH) had three sources of information concerning the epidemiology of 
chlamydia, syphilis and gonorrhea infections. The Swiss Surveillance system was constituted of the 
Swiss Network of Dermatology Polyclinics, the Swiss Sentinel Surveillance Network, and laboratory 
reports. Following the modification of the Ordinance in 2006, the Swiss Surveillance system is today 
constituted only of laboratory reports and complementary reports (table 1). The components of the 
official system, namely laboratory reports and complementary reports, will be described as well as the 
components of the previous system, namely the Swiss Network of Dermatology Polyclinics and the 
Swiss Sentinel Surveillance Network because they have helped collecting data on gonorrheal, syphilis 
and chlamydial infections in the past years. 
 
Table 1: Years of contribution of the different networks 
 
 
 
3.1.1 Laboratory reports  
Laboratory reporting of gonorrhea, syphilis and chlamydia to the SFOPH began in 1987 when the 
federal ordinance on reported infectious diseases was changed. Because of declining cases of syphilis 
and the lack of specificity regarding the information collected, syphilis infection was removed from 
the list in 1999. In 2006, the Ordinance responsible for the change in the surveillance systems 
reintroduced the mandatory notification of syphilis infections [17]. Laboratory reports are made by 
recognized laboratories and are nominative for syphilis and gonorrhea only. They contain 
information on the tests performed and demographic data (Table 2). There are approximately 400 
hospitals and private laboratories in Switzerland and approximately 200 of these report cases each 
 14 
year. The total number of tests performed is not reported [18]. Laboratories have a week to notify 
infections. 
 
3.1.2 Complementary report by medical doctors 
Since 2006, doctors have been legally obliged to report every case of syphilis and gonorrhea. This 
obligation does not concern chlamydial infections. As with laboratory reports, complementary 
reports contain the name of the patient and also information on sexual orientation, the nature of the 
relations (casual or stable), the number of partners in the last 6 months, past history of STI, risk 
factors, country of acquisition, clinical symptoms, route of transmission and indication on partner 
notification [19] [20] (table 2). Doctors have a week to report these infections (Appendix 1 and 2). 
 
3.1.3 Swiss Network of Dermatology Polyclinics 
The Swiss Network of Dermatology Polyclinics started contributing to national surveillance in 1989 
as part of a European project to monitor the prevalence of HIV among patients with STI. The 
network comprises six clinics in public university or city hospitals situated in Basel, Bern, Geneva, 
Lausanne and Zürich (two clinics). These clinics see 100 to 200 patients per day, with Geneva 
reporting the largest number. Patients are usually self-referred, but general practitioners and other 
specialists can also make referrals. Screening of asymptomatic patients is not routine and testing is 
done according to clinical judgment [18]. Behavioral risk data is recorded, as well as demographic 
data, such as gender, age, marital status, nationality and canton of residence (table 2). Multiple 
infections diagnosed in one individual at the same clinic visit can be identified, but individuals 
presenting for multiple consultations cannot be identified. The total number of people tested for STI 
is not recorded [18]. This network stopped contributing to the surveillance systems in 2006. It still 
contributes to the surveillance of STI for complementary studies.  
 
3.1.4 Swiss Sentinel Surveillance Network by gynecologists 
Since 1995, the Swiss Sentinel Surveillance Network provided information about STI diagnosed in 
women by gynecologists (table 2). Case reports included information about laboratory diagnosis and 
year of birth. The number of tests performed was not recorded. Multiple infections diagnosed in the 
same person at different consultations cannot be identified [16]. This network stopped contributing 
to the surveillance systems in 2006. It still contributes to the surveillance of STI for complementary 
studies.  
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Table 2: Past and present surveillance systems and the data they generate(d) on STI 
Surveillance system Demographic data Behavioral data
Laboratory reports Name (except for chlamydial  infections) None
[from 1987 to date] Age
Gender
Canton
Year of Birth
Complementary report Name Sexual orientation
(only for syphilis and gonorrhea) Country of acquisition Number of partners in the last 6 months
[from 2006 to date] Past STI record
Drug consumption
Prostitution
Presence of clinical symptoms
Nature of relation
Route of transmission 
Partner’s notification
The Swiss Network of Dermatology 
Polyclinics
Age Drug consumption
l li i Gender Sexual orientation
[from 1989 to 2006] Civil Status Number of partners in the last 6 months
Canton Condom use frequency
Nationality
Country of acquisition 
The Swiss Sentinel Surveillance Network Gender None
[from 1995 to 2006] Year of birth
 
 
 
3.2 EFFICACY OF THE SWISS SURVEILLANCE SYSTEM 
In 2006, the modification of the Ordinance on medical doctors’ and laboratories’ notifications in 
2006 led to a surveillance system constituted of two components: the laboratory reports and 
complementary reports. There are no national clinical guidelines in Switzerland for STI except for 
HIV. Therefore, in the absence of any recommendations, we can presume that it is mainly people 
with symptoms that undergo a screening test [19]. First the efficacy of the networks that were 
previously contributing to the surveillance system will be described, and then the efficacy of the 
present surveillance system will be assessed. 
 
3.2.1 Swiss Network of Dermatology Polyclinics and the Swiss Sentinel 
Surveillance Network 
The Swiss Network of Dermatology Polyclinics and the Swiss Sentinel Surveillance Network stopped 
contributing to the National surveillance system in 2006. Although some additional information was 
lost, this has not led to any major negative consequences. The Swiss Network of Dermatology 
Polyclinics system was an incomplete source of data on STI. STI constituted a small part of their case 
load, and they more often had syphilis cases, particularly those with skin manifestation. Men with 
urethral discharge would be expected to present to an urologist or general practitioners, although this 
can not be confirmed as little is known about sexual health-seeking behaviour in Switzerland [16].  
Reports from this network were also characterized by low levels of representativeness.  They gave 
information predominately on men, because women represented only 8.1% of the established 
diagnoses. Additionally, the polyclinics treated many non-Swiss patients (46% of all patients) and a 
mainly urban population (the polyclinics are located in large urban centers) [18]. 
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The Sentinella system likewise provided only limited information. The system included only few 
gynecologists and each practitioner reported an average of less than one case of chlamydia per year. 
Therefore the number of cases detected by this network was also incomplete and not representative 
of the women in the general population. The number of chlamydial infections diagnosed by the Swiss 
Network of Dermatology Polyclinics and the Sentinella system represented only 2% of the 
notifications made by the laboratories [16]. Before the change in the surveillance system in 2006, 
trends in STI at a national level reported by the three different components of the surveillance 
system were not consistent [16].  
 
3.2.2 Laboratory reports 
Laboratory reports were already part of the Swiss surveillance system before the modification of the 
Ordinance in 2006 and are still part of it. They are considered as the most representative source of 
data on STI. However, the progression of STI cannot be estimated because the number of negative 
tests is not reported. Increased detection of STI might for example be the result of a combination of 
increased testing, a change in the population being tested, increased test sensitivity, changes in 
reporting or true changes in morbidity [16]. Furthermore, the absence of consistent guidelines for 
testing sexually transmitted infections might implicate that only patients with symptoms are tested for 
STI [19]. In addition, it is important to keep in mind that in case of suspicion of a STI, the patient 
might be treated without laboratory testing (syndromic management), so some STI might not be 
registered. Syndromic management is the core intervention in the WHO strategy for delivering care 
to people with STI in resource poor setting where laboratory testing is not available [21]. This is not 
the case in Switzerland. It is difficult to assess the number of infections that is not notified because 
of syndromic management. Furthermore, STI can also fail to be notified because of antibiotics given 
for another disease. The antibiotics might cure the disease but also the STI. 
Laboratory reports are useful to follow trends of syphilis infections, but to follow trends of 
gonorrhea and especially chlamydia they seem to be less useful. In a study published in 2002, the 
authors concluded that the sensitivity of national laboratory reports of C. trachomatis in 1998 was less 
than 5% for women aged 20 to 34 years. It suggests that laboratory reports of C. trachomatis seriously 
underestimate the frequency of infections among women [23].  This study demonstrates the 
limitations of laboratory reports in evaluating the rates of infections that are mainly asymptomatic 
infections, such as chlamydial infections. Consequently, frequencies of gonorrhea infections, which 
may also be asymptomatic, might also be underestimated by laboratory reporting. Ideally, prevalence 
studies to measure the frequency of predominantly asymptomatic infections could complete the 
surveillance systems [23].  
 
3.2.3 Complementary reports 
Complementary reports by medical doctors are obligatory for syphilis and gonorrhea (appendix 1 and 
2). The information contained in those reports help understanding the evolution of STI in our 
society. They are needed to assess risk factors associated with STI. This helps evaluating groups in 
the general population that are more likely to be infected. Furthermore, when high risk populations 
have been targeted, specific prevention measures can be developed.  
However despite the obligation to report, there have been few complementary reports and most 
of the reports submitted have been incomplete. Consequently, demographic data and behavioral data 
are not representative, neither of the population nor of the sub groups. Furthermore the deadlines of 
reporting are rarely respected [19]. Complementary reports are not completely accepted by doctors 
because they are worried about data protections. Recording the patient’s name is one of their main 
concerns [19]. The patient’s name is an important information because it facilitates the notification 
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and follow up of the partner. Partner notification is the process of informing the sex partners of 
people with sexually transmitted infections of their potential exposure to infection, ensuring their 
evaluation and/or treatment, and providing advice about preventing future infection (also known as 
contact tracing) [24]. The aim is to prevent re-infection of the index case (the first patient diagnosed 
with a STI) and onward transmission [24].  It is an essential step in controlling STI. Partner 
notification is recommended by international health organizations and many health authorities [19]. 
In 2006, in Switzerland, even though partner notification is an essential step in controlling the 
epidemics of STI, sexual partners were contacted in only 45% of cases of notified gonorrhea and 
36% of notified syphilis cases [19]. In addition to the problem of data protection, partner notification 
might be unsuccessful because physicians have too little time to initiate or follow-up partner 
notification or they estimate they do not have the skills to take a sexual history and discuss partner 
notification. Another reason might be that the index cases are unable or unwilling to contact their 
sexual partner(s) [24].  
In 2008, there was a modification concerning complementary reports: the notification of the 
name of the patient is replaced by the notification of the patient’s initials. With this modification, the  
health authorities should still be able to contact doctors in case of suspicion of multiple infection 
cases, as well as when the partner notification isn’t clearly indicated [19]. As mentioned above, data 
protection was a major concern for doctors; consequently this modification should hopefully make 
them less reticent about filling complementary reports. However, this modification might not be 
sufficient to improve compliance, because complementary reports are still a relatively new addition to 
the surveillance system. One way forward would be to better inform physicians of the importance of 
the reports. An improvement of the compliance could be made through additional formation to 
physicians on STI to make them more aware of the epidemiological situation. 
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4.  SYPHILIS, GONORRHEA AND CHLAMYDIA INFECTIONS IN 
SWITZERLAND 
4.1 SYPHILIS INFECTIONS 
4.1.1 Description of syphilis epidemiological tendencies between 1988 and 2006 
 
Figure 1: Laboratory reports of Treponema pallidum in women and men by year, 1988 to 2006 [19]          
 
 
 
Between 1988 and 1999, there was a significant decline in the number of cases reported via 
laboratory reports (figure 1). During that period, the reported cases of syphilis fell from 
approximately 350 to 50, a decline of 86%.   This decline led to the cancellation of systematic 
reporting of syphilis infections to the SFOPH in 1999. During the period where syphilis infections 
were not notified to the SFOPH, the number of cases reported by the Swiss Network of 
Dermatology Polyclinics was increasing quickly and in 2003 it had already tripled [22]. This led the 
Health Authorities to reintroduce the obligation of reporting syphilis in 2006. That year, the 
laboratories declared more than 400 new cases of syphilis infections, an 8 fold increase from the 
statistic of 1999 [19].  
In 2006, it was mainly primary (21%) and secondary (23) syphilis that was diagnosed. Latency was 
described in 23% of the cases and tertiary syphilis was declared in 1% of the cases. In 32% of the 
notifications, the stage of syphilis was unknown or not mentioned (appendix 1). 
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Figure 2: Laboratory reports of Treponema pallidum , cases reported for 2006: Age Groups [19]          
 
4.1.2 Patients’ characteristics 
 
In the 2006 reports, syphilis cases concerned mainly men (74%) between the ages of 35-49 (figure 2). 
Women notified as having syphilis belonged to younger age groups. Women between 25 and 29 years 
of age, between 30 and 34 years of age and between 35 and 39 years of age represented the age 
groups the most notified. People under 25 years represented around 8% in each group (figure 2).   
In 2006, 50% of the notifications concerned men having sex with men (MSM), and 45% of the 
infections concerned patients with casual relations (appendix 1) [19].These two behaviors describe 
patients with high risk of STI acquisition and transmission. MSM are an important subpopulation in 
syphilis infections (figure 3). This subpopulation has increased rates of new partner acquisition and 
shorter intervals between new sex partners and both factors enhance sexual spread of infections [4].  
The serological status of HIV when syphilis is diagnosed is not reported in Switzerland, but from 
data collected in a French study, nearly half of the patients  (46%) diagnosed with syphilis were co 
infected and MSM represented 52% of those infected [25].  This statistic highlights the fact that HIV 
and syphilis, as well as other STI, are interrelated. 
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Figure 3: Syphilis 2006: Sexual orientation of cases notified in a complementary report [19]          
 
 
4.2 GONORRHEAL INFECTIONS 
4.2.1 Description of gonorrheal epidemiological tendencies between 1988 and 
2006 
 
Figure 4: Laboratory reports of Neisseria gonorrhea in women and men by year, 1988 to 2006 [19] 
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From 1991 to 1993, there was a declining trend in the annual number of reported cases of Neisseria 
gonorrhea and from 1993 to 1998, the annual number of reported cases was stable, at about 200-250 
cases per year.  Between 1999 and 2006, however, the number of cases declared almost tripled for 
both gender (figure 4).  
 
4.2.2 Patients’ characteristics       
As for syphilis, gonorrheal infections in men were more often notified than in women (figure 4). In 
2006, 889 cases of gonorrhea were declared: 84% were men and 16% were women. Among men, the 
most represented infected age groups were 25 to 29 years old (20%) and 30 to 34 years old (20%). 
Among women, the  most represented infected age groups are 20 to 24 years old (25%) and 25 to 29 
years old (20%) (figure 5).  
In 2006, regarding their sexual orientation, 49% of men declared heterosexual relations, 33% 
homosexual relations and 2% bisexual relations. Among women, 83% declared heterosexual relations 
and 1% homosexual relations [19]. Considering the total MSM population compared to the 
heterosexual population, MSM proportionally have a higher frequency of infections. However it was 
still heterosexual relations that represent half of the infections (appendix 2).  
 
Figure 5: Laboratory reports of Neisseria gonorrhea, cases for 2006:  Age Groups [19]          
 
4.3 CHLAMYDIAL INFECTIONS 
4.3.1 Description of chlamydial epidemiological tendencies between 1988 and 
2005 
After an overall decrease in the number of chlamydial cases reported between 1990 and 1999, 
infections more than doubled until 2006 (figure 6). That year more than 4000 cases were notified and 
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the number of chlamydia infections still appears to be increasing. Many chlamydial infections escape 
detection by the surveillance system.  As mentioned above, a study, carried out in 1998 among 
women attending gynecologists, observed a prevalence of 1.3% among pregnant women and 2.9% 
among women consulting for a check up. The authors assumed that the prevalence of C. trachomatis 
among the check up women was a rough estimate of the prevalence of C. trachomatis among low-risk, 
sexually active women in Switzerland. This prevalence was then applied to the Swiss population 
statistics to provide an estimate of the total number of chlamydia infections in Switzerland. When 
extrapolating those results, the authors concluded that laboratory reports seriously underestimated 
the frequency of C. trachomatis among women in Switzerland. The authors also concluded that the 
estimates of the prevalence of C. trachomatis infections among women consulting gynecologists for a 
check up was also underestimated, because women who consulted public or private hospitals were 
excluded and there was also underrepresentation of foreign women [23]. They estimated that the 
sensitivity of laboratory reports of C. trachomatis among women aged 20 to 34 years old is probably 
less than 5%. This implies that laboratory reports only represent the tip of the iceberg and that there 
are far more cases of chlamydial infections than the 4000 cases reported in Switzerland. 
 
Figure 6: Laboratory reports of Chlamydia trachomatis in women and men by year, 1988 to 2005 [19]     
     
 
 
 
4.3.2 Patients’ characteristics 
 
In 2005, unlike for gonorrhea and syphilis infections, chlamydia infections were more present among 
women than men. 70% of the cases notified concerned women. Furthermore, the younger female 
age groups are more affected by chlamydial infection than by gonorrhea or syphilis. In 2005, 18% 
women were aged between 15 and 19, 37% between 20 and 24 and 21% were between 25 and 29 
[19].  
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In 2005 among men, the 20-24 year old represented 19% of the notifications, the 25-29 year old 
represented 22% and the 30-34 year old represented 17% (Figure 7).  
 
Figure 7: Laboratory reports of Chlamydia trachomatis in 2005: Age groups [19]. 
 
 
 
 
4.4 ANALYSIS OF THE TRENDS OBSERVED FOR CHLAMYDIA, SYPHILIS AND 
GONORRHEA INFECTIONS 
Trends for syphilis, gonorrhea and chlamydia infections are quite similar and they can be divided into 
two periods: before and after 1999.  
Between 1990 and 1999, there was an overall decline in all three infections. It was difficult to 
identify the precise factors causing this decrease, but evidence for at least one factor was identified. 
This factor was the AIDS prevention strategies which began in 1987 with the launch of the STOP-
AIDS campaign (an information brochure was distributed to all households in 1986). Evaluation 
studies found that this campaign was associated with dramatic increases in condom use [26]. This 
change of behaviour had a beneficial impact on chlamydial, gonorrheal and syphilis infections.  In 
relation to gonorrheal infections, there was a second factor which helped also its decline and 
stabilization during that period. It was a new form of treatment introduced in the early 1980s (called 
spectinomycin). This treatment was popular among physicians. In addition to being an effective 
treatment, it was also easy to administer as it involved a single injection [18]. 
Since 1999, the number of syphilis, gonorrheal and chlamydial infections notified has 
continuously increased. When interpreting the increases observed in STI rates, it is important to 
consider the influence of different factors.  First of all, reports are very sensitive to case detection 
rates, so the more screening, the more cases are detected. In 1996, in Switzerland, the health care 
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insurance became obligatory with the introduction of the LAMal. As a result, every citizen had a 
health care insurance and this might have modified the health care seeking behaviour.  However, as 
laboratory reports do not give information either on the number of negative tests or on the total 
number of laboratory tests performed each year, this potential source of bias cannot be evaluated. 
Secondly, trends are also responsive to any changes in the diagnostic test; if the test is more sensitive, 
more cases will be detected. Thirdly, the risk related to the composition of the population being 
tested (case mix) will also influence the trends in reported STI [27]. In fact, the case mix reflects the 
distribution of risks in the population being tested. If more testing is done in high risk groups, more 
infections will be notified [27]. Therefore, the trends observed could reflect a combination of 
increased testing, a change in the population being tested, increased test sensitivity, and true change 
in morbidity [16]. The increases observed in bacterial STI have to some extent been attributed to 
different factors, even though the reasons for these increases remain unclear.  
 A rise in high risk sexual behaviours is thought to be a major reason for increased bacterial STI 
[28]. Trends in STI are thought to be reasonable indicators of changes in sexual behaviour [29]. High 
risk sexual behaviours also place individuals at risk of infection with HIV. In fact, if the 
incidence/prevalence of HIV is high, there is the possibility of high rates of sexual transmission of 
STI and the reverse is also true [30]. This was confirmed in 2002 when Swiss HIV diagnostic 
laboratories reported 25% more positive HIV test results than in 2001. This was a worrying change 
in the trend, since numbers of positive HIV tests in Switzerland had previously fallen each year since 
1991[31]. Two groups have been particularly affected by this increase: Swiss MSM and heterosexually 
infected immigrants from countries with a widespread HIV epidemic and high HIV prevalence. 
Heterosexual relation is still the main transmission mode for HIV, but homosexual relations 
proportionally represent more cases [31].  A proportion of MSM has been identified as returning to 
higher risk sexual behaviours such as unprotected anal penetration with casual partners [26]. At the 
moment, a decrease in condom use in the general population has not been identified, but it is 
important to be cautious because of the increasing number of STI and HIV cases notified and the 
fact that STI are also increasing in other countries. Sexual behaviour is one of the key factors for STI 
transmission. There seem to be a declining readiness for “safer sex” that may be caused by at least 
three factors: 1) Young adults who have not experienced the first HIV prevention strategies. HIV 
prevention today is far less visible than when the first prevention strategies were introduced. It is 
important that prevention messages are reiterated. 2) The weariness of already sexual active 
individuals who return to higher risk taking behavior [32] [1] and 3) the presence of highly active 
antiretroviral treatment which may reduce the fear of HIV [33]. 
A second factor for consideration is that HIV and STI share some risk factors but not all risk 
factors. Unprotected oral sex, while presenting a relatively safer alternative to penetrative sex with 
regard to HIV transmission, is a very effective way of transmitting syphilis, gonorrhea and chlamydia 
infections [34]. So even if the safer sex rules (no penetration without a condom and no sperm or 
menstrual blood in the mouth) established mainly for the HIV epidemic are respected, the risk of 
transmission of chlamydia, gonorrhea and syphilis is high. The general population needs to be aware 
of this difference in the probability of transmission. To some extent, unprotected oral sex is 
responsible for the return of bacterial STI. The transmission of these infections by unprotected oral 
sex probably indicates a lack of knowledge about transmission risks, arising from an incorrect belief 
in “safer sex” rules [1]. Furthermore, among MSM, a new sexual behaviour appeared in reaction to 
the HIV epidemic, named serosorting. This is the practice of deliberately selecting partners of the 
same HIV status for unprotected casual anal sex. Serosorting amongst gay men has been defined as 
“discussing HIV status with potential partners and only engaging in HIV risk behaviour with those 
they believe are of a similar HIV status” [35]. Serosorting is used as a deliberate strategy to replace 
consistent condom use with casual partners. It is highly problematic because even if both partners 
are indeed HIV-negative or positive, there is still a risk of other STI transmission and acquisition. 
Additionally, HIV status is sometimes assumed rather than actually known [35]. Specific information 
about transmission risks of bacterial STI should be provided to the population and to the sub groups, 
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so people can protect themselves correctly. 
In relation to gonorrhea specifically, there is another reason which might also explain the 
observed increase. N. gonorrhea is becoming more and more resistant to antibiotic treatment. In the 
mid-1990s, high levels of penicillin resistant N. gonorrhea were reported in many large metropolitan 
areas across Europe. By late 1990s, resistance to fluoroquinolone was also observed and more 
recently resistance to ciprofloxacine was documented [36]. Treatment failure facilitates disease 
transmission and may also contribute to increased diagnoses [37]. 
By looking at bacterial STI trends across Europe, it might be possible to further explain the 
etiology of increase in STI in Switzerland. Many European countries are experiencing similar trends 
in STI. It is difficult to compare disease’s rates across Europe because the overall picture has to be 
assembled from sources that vary in their coverage, their completeness and representativeness. Direct 
comparisons of absolute numbers and rates may be misleading since the proportion of diagnosed 
cases reported differs substantially [38]. Additionally, variations in STI screening, partner notification 
and treatment practices also influence the degree to which asymptomatic patients and sexual contacts 
are diagnosed, treated and recorded in surveillance statistics [36]. However, despite these differences, 
the figures 8, 9 and 10 show that, like Switzerland, chlamydia, gonorrhea and syphilis are increasing in 
other countries. A number of broad similarities in STI trends can be observed across Europe: 
• Rates of reported chlamydia infection have increased in all European countries, except 
Estonia and Lativia over the past ten years (figure 8) [38]. 
• Rates of reported gonorrhea in the past ten years has increased in Western Europe, with 
the exception of Italy, Portugal and Spain (figure 9) [38]. 
• Rates of reported syphilis have increased in nine out of 16 Western European countries 
(figure 10)[38]. 
The consistency of trends across Europe suggests that major societal and behavioural 
determinants of STI transmission are operating in tandem in addition to the change in sexual 
behaviours. The changing demographic, social and economic structure of Europe  (decrease 
marriage, delayed childbirth, population movement) will have implication for sexual health. These 
determinants will future described in section 5.1.1. Nevertheless, sexual behaviour is the key 
determinant of STI transmission and it undoubtedly contributed largely to the changing disease 
epidemiology observed in Europe [36]. 
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Figure 8: Rate of reported Chlamydia cases per 100 000 population in selected European countries: 
1997-2006 [39] 
 
 
 
 
 
Figure 9: Rate of reported gonorrhea cases per 100 000 population in Western Europe: 1997—2006 
[38] 
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Figure 10:  Rate of reported primary, secondary and early latent syphilis cases in Europe: 1997-2006 
[38] 
* Primary and secondary stages only (Slovenia 1997-2000) 
 
  In conclusion, the similar changes in bacterial STI epidemiology occurring across European 
countries, and the increasing fluidity of national borders point towards common causative factors but 
also towards common priorities and a need for shared solution [40]. The collaboration of Europe 
(including Switzerland) on STI surveillance, prevention and control would enable comparison of 
disease rates and trends between countries and increase our understanding of the underlying factors 
driving STI transmission. It would also aid in the design and implementation of effective 
interventions [40]. 
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5. PREVENTION OF CHLAMYDIAL, SYPHILIS AND 
GONORRHEAL INFECTIONS 
5.1 THE ROLE OF PREVENTION 
Public Health authorities have four main activities: 
• Disease prevention and health promotion including: 
o controlling transmitted diseases 
o environmental hygiene 
o individual health education 
• Organization of the health care system  
• Health population monitoring, including 
o  actual and future distribution of diseases and their risk factors. 
• Assessment of the efficacy and efficiency of the health interventions. 
 
The control of STI is a public health priority and one that has become even higher with the HIV 
epidemic. Prevention can be primary, secondary and tertiary (figure 11) and there are different 
strategies of prevention: the population strategy and the high risk strategy. The population strategy 
changes risk factor distribution in the entire population. On the contrary, the high risk strategy 
focuses on groups, such as MSM or individuals whose risk of developing infections is above average, 
thereby allowing the adaptation of the preventive message. The main advantage of the population 
strategy is that it modifies the behaviour of the population. The inconvenience is that the individual 
benefit is only slightly perceptible because there is little motivation of individuals. The success of 
population strategy largely depends on the extent to which individuals take personal responsibility for 
their own health by avoiding high risk sexual behaviours. For the high risk strategy, the advantage is 
that it is aimed at high risk individuals that are more motivated because of their own high risk. The 
disadvantage is a low impact, because high risk individuals do not generate the largest number of 
cases.  
The objectives of STI prevention are to reduce the prevalence of STI by interrupting their 
transmission, reducing the duration of infections and preventing the development of complications 
[2]. STI have effects on individuals, their partnership(s) and their sexual network, and the wider 
population; therefore prevention should act at all these levels. For the individual, effective case 
management should cure the infection, prevent re-infection and acquisition of new infection and 
prevent sequelae, but might not have any impact on transmission at the population level. For the 
sexual partnership, partner notification is the appropriate intervention to treat the partner(s), prevent 
re-infection of the index case and, possibly, onward transmission. In order to control transmission 
within wider sexual networks and populations, an effective organized strategy for early detection and 
treatment would be required [24]. 
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Figure 11: The evolution and prevention of disease 
.  
 
 
5.1.1 Primary Prevention 
Primary prevention involves preventing both exposure to and acquisition of STI by means of lifestyle 
counseling, health education and population strategies. Clinician play an important role in the 
primary prevention by asking questions about risk-taking sexual behavior, by encouraging screening 
tests for those at risk, by ensuring that sex partners are evaluated and treated, and by giving advises 
about safer sex practices [14]. Promotions of condom use and information campaigns on STI are 
part of primary prevention. Primary prevention is an important step in controlling STI, because in 
order to avoid a future epidemic there is a need to protect people who are not already infected. The 
prerequisites for primary prevention are the existence of risk factors that can be modified and 
controlled. 
 
 
Risk factors associated with STI 
 
Transmission models of infectious diseases have identified a wide range of factors which are likely to 
exert an important influence on the frequency of sexually transmitted infections. All these factors 
may have participated with varying importance to the increase of STI observed in the last decade. 
These can be divided into different groups: 
• Sexual behavioral factors: sexual contact rate, type of contact, sexual mixing patterns, condom 
use… 
• Biological factors: period of infectiousness, incubation period, infectivity, fatality… 
• Behavioral factors: health seeking behavior 
• Migration 
• Structural,  Economic and Social Factors  
 
 
 Sexual behavioral factors 
The most frequent risk factors which are associated with STI are related to sexual behaviours. 
Increased risk of infection has been associated with early age of first intercourse, multiple partners 
and inconsistent condom use. 
 
Risk Factors Preclinical 
disease 
Clinical 
disease 
Disease’s 
Consequences 
Primary  
Prevention 
Secondary  
Prevention 
Tertiary 
Prevention 
 30 
Figure 12:  2002, proportion of people who had casual partners in the last six months and condom 
use by age group [26] 
 
   17-30 years old                                               31-45 years old 
 
  Always a condom    Had casual partners 
 
 
 
Figure 13: 2002, proportion of people who had a new stable partner in the last year and use of 
condom by age group [26]. 
 
                            17-30 years old                                               31-45 years old 
 
Always a condom    new stable partner 
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In the general population, HIV prevention had an important impact on the use of condom. The 
systematical use of condom has increased between 1986 (first STOP- AIDS prevention) and 2000. 
This increase concerns relations with casual partners as well as stable partners (figure 12 and 13). 
There is a difference of age in condom use as the use declines with the age (figure 14). Men seem to 
protect themselves more than women (figure 14). However, it is important to be cautious when 
interpreting figure 14, because use of condom should be quite similar among men and women. The 
difference in the interpretation of events might explain the lower repartition of condom use in 
women [41]. For example, 16.7% of men include relations without penetration in their definition of 
sexual intercourse but only 1.4% women include this in their definition of sexual intercourse (figure 
15).  
 
Figure 14: Sexually active people in Switzerland having used a condom in there last sexual intercourse 
[41] 
 
Figure 15: Proportion of men and women including relations without penetration in their definition 
of sexual intercourse [41] 
 
 
 
  To sleep with someone  sexual intercourse 
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In the general population, HIV prevention has an impact on condom use. However, it has only 
minor effects on other sexual behaviours, such as number of partners. For example, the median 
number of sexual partners has been stable from 1986 to 2000 in the different age groups and among 
men and women [26]. This stability has been observed for casual relations (figure 12, lower line) as 
well as for stable relations (figure 13, lower line). Therefore, in the general population, the main 
impact of HIV prevention on sexual behaviours is the increased use of condom in stable and casual 
relations. The increased use of condom between 1986 and 2002 has been confirmed by the sales of 
condoms during that period, which have increased considerably (7.1 million condoms in 1986 to 18.1 
million in 2002) [36]. On the other hand, among MSM, the level of protection has decreased for anal 
sex as well as for oral sex. The proportion of MSM having unprotected anal penetration with a casual 
partner has increased from 10 % in 1994 to 19% in 2000. Preventive behaviours are declining more 
in older MSM population [26]. Furthermore, seropositives have more unprotected relation with 
casual partners than seronegatives or untested individuals. Some characteristics have not changed 
since the beginning of the nineties. MSM still have a high number of sexual partners (figure 16) and a 
higher frequency of sexual intercourse [36]. Overlapping and multiple sex partners are also high risk 
sexual behaviors for STI. The probability of exposure for an infected person is function of both the 
number of new sex partners and whether any given partner is infected, which is determined by the 
prevalence of the infection within a community [42]. MSM have more partners than heterosexuals, 
61% are reported to have more than 5 partners in a year, while 83% of heterosexuals have between 1 
and 5 partners in a year (figure 16) [25]. One in five homosexuals has more than 20 partners per year. 
Figure 16 Number of partners in the last year reported by syphilis cases, classified by sexual 
orientation, France 2000-2005 [25] 
 
  
 
 
 
 Biological Factors 
The probability that an infection will occur after exposure is primarily a function of biological 
variables, including factors related to the pathogen, the infectiousness of the source and the 
susceptibility of the host. At the population level, the spread of a STI can be described  in terms of 
case reproduction ratio (Ro) which, for a STI, depends upon efficiency of transmission (b), the mean 
rate of sexual partner change (c) and the average duration of infectiousness (D), as expressed in the 
term: 
Ro= b*c*D 
The higher the value of Ro, the greater the potential for the spread of the infection [2]. 
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Syphilis, gonorrhea and chlamydial infections are characterized by asymptomatic periods. 
Asymptomatically infected males and female contribute disproportionately to syphilis, gonorrheal 
and chlamydial transmission, because symptomatic individuals are more likely to cease sexual activity 
and seek medical care [5]. This asymptomatic state tends to increase the average duration of 
infectiousness, because the infection goes undetected and it can be transmitted. Screening programs, 
in theory, should reduce Ro through reduction in the duration of the infection, by detecting 
asymptomatic and symptomatic infections [27].  
Measures related to the biological predisposition to STI infectivity would be desirable. In the 
adult years, sexual and health behaviours are believed to outweigh biological factors as determinants 
of the incidence of STI infections, but the contribution of physiological factors cannot be 
overlooked. Among women, developmental changes in a number of physiological factors, such as the 
resident flora and acidity of the vagina and the characteristics of the cervical mucus, affects 
susceptibility to STI and their sequelae. For example the menstrual cycle appears to influence the risk 
of upper reproductive tract infection in women, and sexual intercourse during menstruation is 
associated with a higher STI risk. Pregnancy is associated with physiological changes that put women 
at higher risk of STI and its consequences because host defenses are normally suppressed during 
pregnancy.  Among men, however, little is known about analogous physiological changes that might 
affect an individual’s risk of infection with STI [42] 
 Behavioural factors 
STI is also function of health care behaviour of individuals and groups. This behavior can either 
sustain STI in the population or help to control it. The probability that an infection will lead to a 
disease is influenced chiefly by health care-seeking behaviour, which in turn is determined by such 
factors as the individual’s willingness and ability to obtain health care services, as well as the 
availability, accessibility and cost of health care in the community. In Switzerland, health care costs 
are reimbursed only if the patient has reached his deductible. Therefore, deductible might be holding 
back individuals to seek care, because testing and treatment might not be reimbursed. Once health 
care services have been obtained, compliance with the therapy largely determines whether the 
infection will progress to a disease [42]. In general, women are more likely than men to seek health 
care. However, care for STI seems to be an important exception to this observation for several 
reasons. Firstly, STI among women are far more likely to be asymptomatic than infections in men. 
Secondly, when symptoms do occur, they are generally less obviously attributable to STI in women 
than in men. Thirdly, seeking health care from a STI clinic may be more stigma laden for women 
than for men [42]. 
Men and women of higher socioeconomic status have better health care seeking behaviours. 
Furthermore, they tend to have lower risk sex partners because those belong to the same 
socioeconomic group which is associated with relatively low STI rates [42]. The probability of an 
individual developing an outcome depends in part of the prevalence of the outcome in the group to 
which he or she belongs. The prevalence of the behaviour may in turn be influenced by social norms 
regarding its acceptability and desirability. The influence of social norms also applies to sexual 
behaviours [43]. 
 
 Migration 
Population movement by international migration from countries with high STI prevalence and 
travelling overseas are other important factors influencing sexual health [44].  STI have been 
associated with travel and indeed blamed on travelers (particularly on foreigners) since they were first 
described. As we know, tourism is one of the world’s biggest industries. For example, in 1993, UK 
residents made 36 millions visits to foreign countries and 19 million foreigners visited the UK. In 
addition to such tourism, the UN High Commission for Refugees estimates that there are at least 20 
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millions refugees in the world who have fled from their countries of origin, and that there are some 
30 million migrant workers. All these migrations drastically increase the rate of STI propagation [44]. 
European countries are still a major recipient of asylum applications. International migration may 
pose a particular challenge for sexual health as individual may arrive from, or have contact with, high 
STI/HIV prevalence countries of origin, thereby increasing their own STI acquisition risk [36].  
In Switzerland, in 2006, gonorrhea was more often acquired in Switzerland (60%) than in foreign 
countries (13%) (appendix 2), whereas for syphilis (appendix 1), 24% of the patients acquired the 
infection in foreign countries as compared to 13% in Switzerland [19]. 
 
 Structural, Economic and Social Factors 
It is clear that access to appropriate detection method and treatment is a factor that can influence 
rates of STI. In Switzerland, the access to hospital or any medical doctor and appropriate detection 
method and treatment has been evaluated as good, even in rural areas.  
On a different note, the recent decades have seen the evolution of human societies.  There is 
increasing urbanization and globalization [45]. Chlamydial, syphilis and gonorrheal infections tend to 
be higher in urban residents. In 2006, in Switzerland, more than 80% of cases of syphilis were 
declared by 7 cantons: Geneva 28%, Zürich 19%, Vaud 19%, Bern 8%, St Gall 4%, Tessin 4%, and 
Basel 2% [19]. Additionally, in industrialized countries, the institution of marriage and family has 
been evolving, with greater proportion of individuals being single as a result of decreasing marriage 
rates and increasing divorce rates. People are settling down later thereby widening the time period 
available for sex partner acquisition, a key determinant of STI transmission [36]. 
In conclusion it can be said that the control and prevention of STI depend on a more 
comprehensive understanding of the social and behavioral patterns involved. While sexual and health 
care behaviors can be neither legislated nor controlled in any society, it might be possible to influence 
them if we knew enough about their determinants and how to put in place appropriate behavior 
modifications [42]. Even when well informed, some individuals continue to have high risk sexual 
behaviours. Taking into account their social and affective environment, counseling could help them 
assessing their own risk and finding their own prevention strategies. Health insurance deductibles 
might also create an obstacle to health care seeking behaviours; offering counseling or a free check 
up to young adults could help get around the deductible problem. Additionally, separate education 
programs for target groups must each contain clinically relevant information about STI and sexual 
health. Each program should teach the appropriate and relevant behavioural skills needed for both a 
healthy sexual lifestyle and STI prevention. For example, STI risk is different for a gay adolescent 
than for a 35-year-old person in a long term monogamous, heterosexual relationship [36]. 
Additionally, it is important to have a surveillance system that can collect demographic and sexual 
behaviour data. Without an efficient collection of data, the risk factors of each STI might not be 
assessed correctly. At the present time in 2008, Switzerland does not have an effective collection of 
information on patient characteristics. The complementary reports which are supposed to contain all 
those information are not filled out regularly by doctors reporting STI. The SFOPH has made some 
modifications to facilitate their participation, but they need to encourage, and inform medical 
professional more strongly in order to get them more involved in STI prevention. 
 
5.1.2 Secondary prevention 
Secondary prevention is likely to play a critical role in the prevention of STI. The aim is to reduce the 
prevalence by shortening the duration of the infection by: 
• Promotion of early health care seeking behaviour 
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• Accessible, effective and acceptable care 
• Education and counseling 
• Early detection and treatment of asymptomatic infection through screening 
• Partner notification [2]. 
 
The general prerequisites for disease prevention by screening are a high prevalence, significant 
morbidity, an available diagnostic test and last but not least, the disease must be treatable. Chlamydial 
infections seem to be the ideal candidate for screening, because it fulfills all the prerequisites [14]. 
Prevalence is an important parameter for screening procedure because if it is low, the screening 
might not be cost effective. In that case, it is important to define target groups to whom the 
prevention procedure will be recommended. 
 
5.1.3 Tertiary prevention 
Tertiary prevention generally consists of the prevention of disease progression. In the case of 
chlamydial and gonorrheal infections, it consists of preventing the complications of the infections 
such as PID or infertility. In the case of syphilis, it consists of diagnosing the infection early enough 
to prevent tertiary syphilis and its serious complications, such as neurosyphilis or visceral 
complications. Unlike primary and secondary prevention, tertiary prevention is made primarily by 
health care practitioners. 
 
5.2 WHAT IS SWITZERLAND ACTUALLY DOING FOR THE PREVENTION OF 
CHLAMYDIA, SYPHILIS AND GONORRHEA INFECTIONS? 
Switzerland is recognized internationally for its prevention campaign LOVE LIFE- STOP SIDA 
[46]. This campaign was awarded several prizes and the British Medical Journal even published an 
article on the campaign [47]. Unfortunately the prevention of STI already stops there, because it 
mainly focuses on HIV. The prevention strategies for HIV encourage the use of condoms and safer 
sexual practice but always in relation to HIV. It is clear that chlamydial infections and especially 
syphilis and gonorrhea infections share some risk factors with HIV infections. Therefore, change in 
high risk sexual behaviours will also influence rates of STI, but as explained before, STI also have 
their own risk factors, such as higher transmission with oral sex. Specific information on STI is not 
given to the general population or to the sub-groups. This means that the population at risk might 
not know the consequences of these infections, the symptoms they produce or the risk factors 
associated.  
Chlamydial infections lead to a separate problem, because a high proportion of the target 
population does not belong to the main target groups of the HIV prevention. The latter are similar to 
gonorrhea and syphilis target groups, such as MSM, drug users, sex workers and clients, migrants and 
travelers [19].  On the other hand, the target group for chlamydial infections is sexually active young 
women and men. A study carried out in the UK population revealed that only 26% of people aged 
16-24 years had heard of chlamydial infections and 68% of these did not know what symptoms or 
conditions arise from infection with chlamydia [60]. It can be expected that the level of knowledge 
about chlamydia in the sexually active Swiss population will also be low. Therefore, the population 
vulnerable for chalmydial infection might not know that they are at risk of sequelae such as ectopic 
pregnancy or infertility. 
In Switzerland, sexual education is taught to young people, but there is a big heterogeneity in its 
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organization. In some cantons, the teacher is responsible for sexual education and in other cantons, it 
is an external professional. There is a good coverage for young students, but from 15 years of age the 
coverage is very heterogenic. The coverage is better in Suisse romande than it is in Suisse alémanique. 
Sexual education is an important prevention strategy for HIV/AIDS. The themes taught during 
sexual education differ from canton to canton [26]. Therefore STI, other than HIV, might not be 
discussed during sexual education classes. In addition, it is not possible to influence how much these 
young people are going to remember.  
Switzerland has no national guidelines on STI except for HIV and no screening programs 
organized for chlamydia, gonorrhea and syphilis infections. The only screening that is performed in 
Switzerland is for syphilis in pregnant women [19]. This lack of national guidelines means that it is up 
to the willingness of the doctor to inform and estimate the risk of his patient for any of these 
diseases. During the personal history taken of a young adult by a medical doctor, sexuality is 
investigated in 49% of the cases [48]. By comparison with other public health topics, sexuality 
occupies a secondary place in the preventive practices of Swiss primary care physicians report. 
Alcohol or tobacco consumption, as well as physical activity are themes that physicians report almost 
systematically during a first non urgent consultation with a new patient. Overall 9 patients in 10 
would like their doctor to ask them about their sexual life in order to receive counseling, while 85% 
would not be embarrassed if asked such a question and 57% consider themselves not well informed 
about STI. Despite these wishes, only 41% has ever experienced a “general discussion” on their 
sexual life with their doctor [41]. These statistics seem exceptionally low knowing that doctors play 
an important role in primary prevention by asking questions about risk taking behaviour and if 
needed, encouraging screening tests. There is clearly a need to issue clinical practice guidelines for the 
management of STI. This should be carried out by a recognized national professional body. STI’s 
guideline should include recommendations about diagnosis, antibiotic treatment, partner notification, 
clinical follow up and reporting of cases. It should also contain recommendation for repeat or follow 
up testing of people with a diagnosed STI [24]. 
Regarding the prevention made for chlamydial infections, a project named SCREen developed a 
typology of chlamydia control activities in order to categories European countries and their actions 
to control the spread of chlamydial infections [24]. The aim of this typology is to monitor the 
intensity of chlamydia control activities in each country, but it is also a tool to assist decisions on 
control activities that should be strengthened or introduced. Information about guidelines, chlamydia 
testing and partner notification provided in countries taking part in the project were classified in five 
categories of chlamydia control activities: 
• No organized activity: Countries have no guidelines for effective diagnosis and management 
of diagnosed chlamydial cases. 
• Case management: Countries have guidelines for at least one group of healthcare 
professionals, recommended by an appropriate professional organization 
• Case finding: Guidelines cover partner notification 
• Opportunistic testing: Guidelines state that at least one specified group of asymptomatic 
people is offered chlamydia tests. 
• Screening programs: Organized chlamydia screening is available to a substantial part of the 
population. It is a planned program with clear objectives. 
 
Switzerland is classified in “no organized activities” with eleven other European countries. This 
group includes countries with the highest per-capita GDP (Liechtenstein and Luxembourg) and the 
lowest per capita GDP (Turkey and Bulgaria). There is non consistent association between the per-
capita GDP of a country and the intensity of chlamydia control activities (figure 18) [24]. 
 
Figure 18: Category of chlamydia control activity by country and per-capita GDP in €, for countries 
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participating in project SCREen [24].  
. 
5.3 WHY IS IT IMPORTANT TO PREVENT CHLAMYDIA, SYPHILIS AND 
GONORRHEA INFECTIONS? 
Chlamydia, syphilis and gonorrhea are three infections with high burden on the society. They have an 
impact on the health of the population, but they are also a financial burden. As we have seen in 
section 2, those STI have consequences on women’s reproductive health such as pelvic inflammatory 
diseases, tubal infertility and ectopic pregnancies and among men they may cause proctitis, 
epididymitis and also infertility. Not withstanding the human costs, a major problem is also the 
healthcare costs. The United Kingdom has estimated the healthcare costs of chlamydial infections at 
50 million pounds per year [49]. The total economic burden of a disease in the society includes both 
direct and indirect costs. Regarding direct medical costs, the screening, diagnosis and treatment of C. 
trachomatis only represent a fraction of this amount. It requires relatively little money to screen for 
infection and to treat infected individuals with antibiotics. However, when irreversible tissue damage 
has already taken place, the cost of treating the sequelae is high. Furthermore, indirect costs also have 
to be considered. Those are composed of the loss of workplace productivity attributable to 
morbidity. Loss of productivity is not negligible and it imposes a notable burden on society in general 
and on employers in particular [50].  
Apart from being serious diseases in their own rights, STI enhance the sexual transmission of 
HIV infection. The presence of untreated STI, ulcerative or non ulcerative can increase the risk of 
both acquisition and transmission of HIV by two to four-fold [51]. Ulcerative STI increases male 
susceptibility approximately fourfold and female susceptibility about threefold, whereas non 
ulcerative STI increase male susceptibility threefold and female susceptibility twofold. Due to the 
greater frequency of non-ulcerative STI in many populations, they may be responsible for more HIV 
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transmission than ulcerative STI [52]. The evidence points towards important positive bidirectional 
interactions between HIV and STI. They may therefore reinforce the spread of each other and lead 
to a synergistic amplification [53].  
Results from a study conducted in Tanzania suggested that improving the management of STI 
can reduce the incidence of HIV-1 infection in the general population by about 40% [54]. 
Furthermore, this intervention has been shown to be highly cost-effective. However, this finding was 
not confirmed by a trial carried out in Uganda [55]. Mathematical modeling studies that investigated 
differences in the results of the general population trials in Tanzania and Uganda suggest that 
improved services and mass treatment had much the same effect on STI. The effect on HIV 
transmission, however, was dependent on the role of concurrent sexually transmitted infections in 
promoting new HIV infections in epidemics at different stages. The earlier phase of the HIV 
epidemic in Tanzania and higher frequencies of risky sexual behaviour at the time of the intervention 
could explain the greater effect on HIV incidence in Tanzania than in the Uganda trials [21]. 
Regarding chlamydial infections, there are few studies on this infection and increased transmission of 
HIV. One group found that PID was strongly associated with HIV acquisition. Although PID itself 
would be unlikely to increase HIV transmission risk, it may be assumed that PID is a proxy for 
previous infection with gonorrhea, chlamydia or other pathogens. For syphilis and gonorrhea 
infections, there are strong evidences that they facilitate HIV transmission [51].  
Chlamydia, syphilis and gonorrhea infections are a real public health burden in Switzerland. The 
quantity of infections in Switzerland has been rising in the past decade and consequences of 
untreated infections are still present, implying both direct and indirect costs. The fact that these 
infections are easily diagnosed and treated with antibiotics should encourage the SFOPH to take 
measures to prevent them. Furthermore, STI and HIV epidemics are interdependent. Early STI 
treatment should therefore be a part of a high quality, comprehensive HIV prevention strategy [52]. 
Monitoring trends in STI provides also valuable insight into the likelihood of the importance of 
sexual transmission of HIV within a country [26]. Even if, in the end, it is found that STI have only a 
limited impact on HIV transmission, it is impossible to miss the potentially cost-effective chance of 
decreasing and controlling HIV transmission through their treatment [53].  
 
5.4 THE EXAMPLE OF THE UNITED KINGDOM 
The United Kingdom, like Switzerland, is experiencing rising levels in the number of cases of 
chlamydia, syphilis and gonorrhea that are recorded. The United Kingdom’s surveillance system is 
based on a network of genitourinary medicine clinics (GUM clinics) that are treatment centers solely 
for the management of acute STI. Statistical returns from GUM clinics form the basis of their 
national STI surveillance programs. Data on STI diagnosed outside of this setting are captured by 
laboratory reporting or special sentinel surveillance programs [36]. 
N. gonorrhea is the second most common bacterial STI diagnosed in the United Kingdom after C. 
trachomatis.  In 2005, the rate of diagnoses in men was more than twice as high as that seen in women. 
There has been a gradual decline in the number of diagnoses since 2002 (figure 19). The fall 
consisted of an 11% decrease among men, of which 18% was among heterosexual men and 18% 
among women. This is an encouraging sign, however, over the past decade, there has been a rise in 
diagnoses of gonorrhea among MSM with the highest numbers diagnosed among those aged 25 to 34 
(figure 20). Between 2000 and 2005, there was a 39% increase among MSM. This point towards the 
fact that gonorrheal infections are getting concentrated among high risk groups, such as MSM.  
Diagnoses are still increasing among MSM, while there is a decrease in the general population. 
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Figure 19: Rates of uncomplicated gonorrhea infection by gender and age group, United Kingdom:  
1996-2005 [56] 
 
 
 
Figure 20: Diagnoses of gonorrhea among MSM by age group, United Kingdom: 1996-2005 [56] 
 
Unlike Switzerland, the United Kingdom has edited national guideline on the diagnosis and 
treatment of gonorrhea in adults in order to standardize the case management of patients with 
gonorrheal infections [57]. This guideline encourages physicians to give information on the infection, 
and its long term consequences as well as oral and written information on STI and their prevention. 
It encourages also screening for chlamydial infections for every positive gonorrheal diagnosis and 
partner notification. The United Kingdom has also established in the year 2000 a program named the 
gonococcal resistance to antimicrobials surveillance program (GRASP) which monitors antimicrobial 
resistance to N. gonorrhea in England and Wales [58]. As explained before, the multi resistance of N. 
gonorrhea to antibiotics might have been one of the reasons for the increase observed in the past years. 
Therefore, GRASP is an important strategy for controlling gonorrhea infections.  
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Figure 21: Rates of primary and secondary syphilis infection by gender and age group, United 
Kingdom, 1996-2005 [56]. 
 
 
Between 1996 and 2005 (figure 21), there was a huge increase in diagnoses of infectious syphilis in 
GUM clinics in the United Kingdom. This increase has been punctuated by a series of outbreaks 
occurring mainly in large cities. The largest outbreak started in London in 2001 and since then there 
has been a steep rise in infections, particularly among men [56]. In 2005, 829 cases were reported. Of 
these, 68% were among MSM and 45% were reported as acquired through oral sex. Failure to 
effectively rupture transmission chains within the initials spread network has probably resulted in 
extension of the outbreak to adjoining and distant cities (through migration, travel…) and to lower 
risk networks [34]. As for gonorrhea infections, there is a guideline implemented for syphilis 
infections [59]. The fact that the United Kingdom has national guidelines indicate that they have 
realized the burden that bacterial STI represent and are trying to find innovative intervention to 
control their spread. An intervention that is really interesting is the implementation of a national 
screening program for early detection of chlamydial infection, named National Chlamydia Screening 
Program (NCSP). Screening is testing for asymptomatic chlamydia in people who do not know they 
are infected with the intention of preventing future morbidity [22].  
Figure 22: Rates of uncomplicated genital chlamydial infection by gender and age group, United 
Kingdom: 1996-2005 [56]. 
 
 
The number of diagnoses of chlamydial infections made in GUM clinics has increased of three 
fold between 1996 and 2005. Between 2004 and 2005, the increase appears to be slowing down with 
an increase of only 7% among men and 3% among women. In 2005, highest rates of diagnoses in 
women were among the 16-19 and 20-24 year groups, and in men highest rates were among those 
aged 20-24 years. This distribution is similar to the one observed in Switzerland. The rise in 
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diagnoses of chlamydial infection since the mid-1990s is probably due to the same combination of 
factors described for Switzerland. Additionally, in the United Kingdom the increase in chlamydia 
diagnoses might also be explained by the implementation of a national chlamydial screening program. 
Therefore, there is increased awareness to chlamydia through population-level campaign and also 
increased availability of diagnostic services leading to an increase in diagnoses of chlamydial 
infections [56]. 
In UK, the case for screening began in earnest in 1998 with the publication of a report on 
chlamydia infections which outlined the public health importance of this disease and the need to 
screen high risk individual [60]. Chlamydia pilot testing sites confirmed the significant disease burden 
in the general population (10.1% positivity among women and 13.3% among men) and the 
demographic and behavioural factors associated with prevalent undiagnosed infection [60]. The 
vision was to implement a multifaceted, evidence based, and cost effective national prevention and 
control program for genital chlamydia by 2008. All sexually active adults should by then be aware of 
genital chlamydia and its effects and should be able to access a range of prevention and screening 
services to reduce their risk of infection or onward transmission. Goals for chlamydia screening 
programs are, for the individual, to reduce likelihood of experiencing important health complications 
and sequelae, and, for the population, to reduce the incidence and prevalence of chlamydial infection 
in the population at risk. Reducing prevalence and incidence should also reduce transmission, 
preventing additional cases of reproductive complications. Screening programs, in theory, should 
reduce incidence through reductions in the duration of the infection [27].  
The screening program implemented in England is an opportunistic screening program, which is 
offered to women and men under 25 year old attending traditional and non-traditional health service 
setting [60]. Opportunistic screening is the approach where individuals who are attending a health 
care setting for any reason (not necessarily related to sexual or reproductive health) are offered the 
opportunity to have chlamydia screening test [24]. A broad number of locations are offering 
chlamydia screening. These include contraceptive clinics, general practices, young people’s services, 
antenatal services, infertility units, and termination of pregnancy clinics. Screening is also encouraged 
to those within the target age group through innovative outreach strategy, such as days at military 
bases, youth clubs, university campuses or health fairs, mobile vans or buses for contact with young 
people and prisons. People falling within the screening guidelines are offered a chlamydia test when 
attending a venue participating in the program, regardless of the reason for their attendance. The 
attendance, itself, is the opportunity created to educate and encourage the uptake of screening for 
chlamydia [61]. In 2006, among women, community contraceptive services is the most common 
screening location (38%) and for men the highest proportion of screens occurred in educational 
settings (17%) [62]. Data from the first year confirm that the epidemiological profile of both men 
and women screened is nearly identical to that found in numerous studies in the UK and in Europe. 
Highest chlamydia positivity is found in women aged 16-19 years and men aged 20-24 years [61]. 
When diagnosed, patients are offered the choice of notifying their own partners (patient referral), 
or supplying information for the health adviser or local chlamydia coordinator to notify the partner, 
without the patient’s name being given (provider referral) [62]. NAAT is the diagnosis test used and 
the recommended interval between screening tests is one year if the previous test was negative, or 
after a change of sexual partner. People with a positive test are recommended to have a test for re-
infection at least five weeks after treatment [24]. There is, at the present, no national guidance about 
how annual repeat screening is to be implemented or monitored [24]. 
The NCSP has been rolled out in phases with full participation in 2008. The first phase started in 
2003.  Screening has been increasing year after year, from just over 17 000 in year 1 to almost 150 
000 in year 4 (2006-2007). In year 4, there is still a positivity rate of around 10% in those screened for 
both young men and women under 25 year old [62]. Coverage aim is to achieve annual chlamydia 
screening coverage of 15% of the population of 15-24 year old.  
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5.4.1 Effectiveness of the national chlamydia screening program 
The NCSP was fully implemented this year. The performance of the NCSP is measured through 
coverage and partner notification.  
Coverage is calculated by dividing the number of screens by the estimated eligible population. Of 
note, tests done in GUM clinics are excluded from these totals as they are regarded as diagnostic 
rather than screening test. This differs from estimates in other countries taken from surveillance data, 
which cannot differentiate between screening and diagnostic test and might therefore overestimate 
the coverage of screening [24]. As seen in figure 23, the coverage varies from one region to another. 
The coverage ranges from less than 1% to 15%. Their target coverage of 15% is still not achieved. 
The long term strategy is to aim for even higher NCSP coverage levels in order to attain the volumes 
needed to reduce prevalence. The new aim for 2008-2009 is a 17% coverage level in the target 
population. One of the keys to success for screening program is to screen sufficiently high 
proportion of the target population and sufficiently regularly. However, effective screening rates are 
30 to 40% [64]. But the effective screening rate will be difficult to attain, because opportunistic 
screening requires presentation to a clinic for screening. Many adolescents and young adults have few 
encounters with health care professionals [27]. Additionally, men are also a difficult target group to 
approach through opportunistic screening. Greater effort will be needed to ensure that men 
themselves are aware of chlamydia, its effects and strategies for its prevention and control [60]. If 
men are not sufficiently tested, rates of re-infection among women will rise. The general practice 
remains the single healthcare setting attended by most young men, perhaps more effort should be 
put into getting young men screened there [65]. The next steps for 2009 are to increase access for 
vulnerable populations, including street youth, young offenders, ethnic minorities and men [62].  
Partner notification is also an important prevention strategy, because if the partner is not treated 
re-infection or further transmission can occur. The aim of the NCSP for partner notification is 0.64 
contacts per case. The average partner notification for the period April to September 2007 is 0.4 
contacts per case, ranging from 0.03 to 0.99 [62]. 
It is difficult to assess the effectiveness of the NCSP because there are no performance indicators 
on key outcomes such as reduced reproductive tract complication, prevalence of chlamydial 
infections and repeat screening [64]. Furthermore, it has only been fully implemented this year. 
However, two countries are often cited as having controlled transmission of chlamydial infection and 
reduced morbidity of the female reproductive tract. They are Sweden and the USA. 
Sweden was the first country in the world to make free testing, treatment and partner notification 
for chlamydia available throughout the country, and to have a national diagnostic and reporting 
system [24]. Swedish researchers were key players in demonstrating the importance of chlamydial 
infection in the 1970s and 1980s. The first documented “program to identify asymptomatics” started 
in 1982 [64]. Intensive chlamydia control activities in Sweden were associated with marked falls in 
chlamydia and ectopic pregnancy rates in women under 35 years, even though, the fall in rates of 
chlamydia infections in Sweden coincided with the national campaign to prevent HIV[66]. 
Furthermore, comprehensive surveillance showed that chlamydial rates doubled in Sweden between 
1997 and 2003 to prescreening levels. However, reports of the effectiveness of screening in Sweden 
persist [64] 
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Figure 23: Proportion of population of the individuals counties screened in UK by the NCSP [62] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the USA, opportunistic chlamydial screening, the Infertility Prevention Program implemented 
in 1995, has also been credited with decreases in rates of chlamydial infections [64]. However, this 
might not be true as the results are not promising so far. A recent report showed that chlamydia 
positivity in women decreased in  two of 10 regions from 2003 to 2004, increased in six, and 
remained the same in two [64].  
Despite these results, desire to believe in the effectiveness of chlamydia screening is maintained 
and is often supported by these two countries [64]. Furthermore, the Swedish and the American 
chlamydial control activities cannot be classified as organized chlamydia screening programs. There is 
misinterpretation of the definition of a screening program [64].  A program has been defined by 
specific criteria and Sweden and the USA do not fulfill all these criteria (figure 24). A screening 
program is defined as an ongoing public health service in which screening is delivered to a 
sufficiently high proportion of the target population at sufficiently regular intervals to achieve a 
defined level of benefit, while minimizing harm, at reasonable cost. It requires a level of organization 
that ensures that the quality of the structures and processes can be assessed and the primary 
outcomes of the program can be monitored [24]. The SCREen project has classified the NCSP as an 
“organized chlamydia screening program”. Only one other country in Europe has been assessed as 
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having an “organized Chlamydia screening programs”, and it is the Netherlands [24]. 
 
Figure 24: Components of national screening programs [24] 
 
The misinterpretation of what comprises a screening program and the desire to believe in them 
has led to uncritical acceptance of the effectiveness of screening programs and the funding of the 
NCSP in England before the benefits and the harms were evaluated [64]. No randomized controlled 
trials have ever evaluated opportunistic screening as they are currently practiced [64]. Randomized 
trials have shown that if people at high risk of chlamydia, because of young age or high risk 
behaviour, are invited to be screened, the incidence of PID one year later can be reduced by about a 
half [64]. These trials provide the evidence supporting the NCSP screening program. The problem is 
that the screening programs in these trials were population based. Women were either solicited to 
present for screening or mailed test-kits directly. On the contrary, the English program is 
opportunistic, offering screening only to people presenting to a clinic for other reasons [27].  
Evidence from trials of proactive screening cannot be extrapolated to opportunistic screening [64].  
Despite an absence of evidence of effectiveness and increasing rates of chlamydia in countries 
that are assumed to have such programs, belief in the success of opportunistic screening persists [64]. 
Countries, such as France, Romania, Slovenia, Ireland, the Netherlands and Australia are currently 
considering introducing screening policies or programs [64]. The Netherlands has already a pilot 
program in three regions of the country that began in March 2007. Chlamydia screening will be 
delivered using a proactive register-based approach, with annual postal invitations sent to men and 
women aged 16 to 29 years. Compared with the NCSP, the target population will be broader and the 
strategy implemented is different (opportunistic screening vs register based screening). Once the 
program is completely implemented in the Netherlands, results from both screening programs will be 
important to compare. 
Screening programs may indeed be an important strategy towards limiting the complications of 
chlamydia infections [27]. However there is a need for a rigorous assessment of the benefits and 
harms of screening programs [64]. Different issues have to be examined before launching a screening 
program: 1) the epidemiology and natural history of C. trachomatis (studies on the progression of 
lower genital tract infection to PID, incidence of neonatal complications, appropriate screening 
intervals), 2) the effectiveness of screening for reducing morbidity (randomized controlled trials to 
examine the effectiveness of opportunistic and proactive chlamydia screening, including more than 
one round of screening) 3) the value for money (cost effectiveness and cost-utility analysis) [64]. 
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6. CONCLUSION 
In line with other European countries, Switzerland has seen the number of cases of syphilis, 
gonorrheal and chlamydial infections rise in the last decade. The medical as well as financial 
consequences engender by these infections should not be underestimated, neither should the risk of 
increased transmission and acquisition of HIV via STI. The situation regarding gonorrheal, 
chlamydial and syphilis prevention in Switzerland needs to change. Rates of STI, but more 
importantly their medical consequences will not decrease without Public Heath interventions.  
Therefore, the SFOPH must take measures in order to control the rising rates of bacterial STI. The 
potential improvements suggested are: 1) the optimization of the surveillance system, 2) providing 
information to vulnerable populations on the risks associated with bacterial STI and ways of 
protection, 3) issuing of clinical guidelines for medical professional. 
 Firstly, it is necessary to optimize the surveillance system, because epidemiological data are an 
important basis for formulating aims and developing countermeasures. Laboratory reports and 
complementary reports are a good combination towards obtaining good surveillance data and also 
good demographic and sexual behaviors data. But this combination still needs to be optimized. 
Regarding the laboratory reports, a very important improvement that has to be envisaged is the 
obligation for the laboratories to declare the total number of tests. This is a necessary step in order to 
assess the evolution of STI and also to evaluate the real burden of the infections [19]. Furthermore, 
the limitation of laboratory reporting is the underestimation of asymptomatic infections, especially 
chlamydial infections. This points towards the need for prevalence studies to complete the 
surveillance data on STI. Regarding complementary reports, they are, at present, not representative of 
the general population or of sub groups, because of lack of compliance from physicians. An 
improvement in health might be obtained by promoting a greater collaboration between laboratories, 
medical staff and the SFOPH. Furthermore, initiation of a culture of reporting would also enhance 
the surveillance and prevention of STI [19].  
Secondly, vulnerable populations must be informed and be conscious of the consequences of 
STI. For gonorrhea and syphilis infections, the target population is the same as for HIV infections; 
those are MSM, sex workers and their clients, migrants and travelers. The failure of these subgroups 
to protect themselves against STI is worrying and indicates either a lack of knowledge about 
transmission risks or complacency about the individual risk of acquiring a STI. Intensive and focused 
control measures in the target groups, especially among MSM, to bring syphilis and gonorrhea under 
control are required, such as targeted health promotion campaigns in Internet chat rooms, in saunas, 
clubs and other meeting points for sex partners. When possible, synergies with HIV campaigns 
should be used, but without neglecting the provision of specific information regarding the risk 
factors associated with gonorrhea and syphilis. In relation to chlamydial infections, a high proportion 
of the target population doesn’t belong to the principal target group of HIV prevention. The target 
group for chlamydial infections is sexually active young women and men. As it is the most prevalent 
of the three infections studied in this “mémoire” and as its target groups are different from the 
HIV’s target groups, it should benefit from more attention from the SFOPH. As chlamydia 
infections are mainly asymptomatic, it is clear that a solution for controlling its spread might be a 
screening program. The primary reason for untreated chlamydial infection is that a large proportion 
of infected persons never have symptoms. This situation points towards the screening program as 
being the most effective way to control chlamydial infections. However, before implementing a 
chlamydial screening program, rigorous assessment of its benefits and harms is required. The long 
term reduction in the prevalence of chlamydial infection seems improbable with the current 
programs, unless a sufficiently high proportion of the target population is screened and that the 
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screening is done at sufficiently regular intervals.  
Thirdly, national Swiss guidelines should be drafted for syphilis, gonorrhea and chlamydia 
infections. These guidelines should contain information on diagnosis, antibiotic treatment, partner 
notification, clinical follow up and reporting of cases. They should also contain recommendations for 
repeat or follow up testing of people with a diagnosed STI [24]. This will standardized the case 
management for these three infections and should make physicians more implicated in prevention of 
STI. Guidelines have already been issued in other countries. An adaptation of these guidelines to the 
Swiss situation is recommended. 
There are many measures that Switzerland could implement to optimize the prevention of STI. 
The country however has not moved quickly enough. This is presumably due to the institutional and 
political frame of Switzerland. It is a federate state with three institutional levels: the Confederation, 
the cantons and the communes. The breakdown of responsibilities between the Confederation and 
the cantons is defined by the federal Constitution in which the article 118 gives the responsibility of 
combating transmitted diseases to the Confederation [67]. It is the Confederation therefore that takes 
decisions concerning STI. However, when decisions are taken in Switzerland, there are many actors, 
governmental and non governmental, that act at the national level, canton level and commune level 
for the prevention and promotion of health [67]. Implementing long term prevention measures will 
therefore need the collaboration of many actors at different levels and high social acceptance [68]. 
Both of these elements are challenging, because making collaboration work between all the actors is 
already complicated and the society might also need to overcome the stigma and prejudice associated 
with STI [21].  
In 2005, 1.13 billion francs were invested in the prevention and promotion of health. This only 
represents 2.1% of the total Swiss health care expense. The budget for health prevention and 
promotion is situated below the average of the OCDE countries, which is of 2.7% [69]. With its 
budget for health prevention being lower than in other OCDE countries, the Confederation has 
chosen to invest money in themes with high visibility such as alcohol, smoking and obesity [67]. The 
problem is that STI lack political visibility and consequently their burden stays unrecognized. The 
decision-makers must be persuaded that strategies to control STI should not solely be tied to HIV 
prevention programs and that investing in high quality and effective intervention will bring its 
independent benefits [21]. For HIV infections, governments have been convinced to invest in 
prevention mainly by macroeconomic arguments about the negative effect of poor health on 
economic growth. The same type of arguments could also convince decision makers for STI. 
However, studies on the economic burden of STI and its prevalence in Switzerland are expensive. 
The solution might be in a wide collaboration with Europe. The consistency of trends across Europe 
points to common causative factors, common priorities and a need for shared solution [40].  Swiss 
decision makers might only realize the burden of STI, when the EU asks for wide collaboration to 
control these infections.  
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Appendix 1: Syphilis: Complementary reports, 2006 [19] 
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Appendix 2: Gonorrhea, Complementary reports 2006 [19] 
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